ISSN: 2278-0238

薬学および生命科学における研究開発の国際ジャーナル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

A CLINICAL STUDY OF DRUG ?DRUG AND DRUG-FOOD STUDY INTERACTIONS ON THE MANAGEMENT OF HYPERLIPIDEMIC DISEASE: SIMVASTATIN, EZETIMIBE AND OMEGA-3- FATTY ACIDS

W. Clement Atlee, M. Vasudevan, Udhumansha Ubaidulla

This study was designed to investigate the effects of combination of ezetimibe, simvastatin and omega-3-fatty acids on lipoproteins in patients with mixed dyslipidemia. Among the 102 patients were screened 98 who met the inclusion and exclusion criteria after 6 weeks on a strict diet therapy were grouped into four treatment groups (2 patients left out in between). The inclusion criteria were mixed dyslipidemia with a high triglyceride level (200-499 mg per 100 ml) and a total cholesterol level more than 200 mg per 100 ml. Present study was conducted on dyslipidemic patients receiving ezetimibe (10 mg) alone, simvastatin (20 mg) alone, omega-3-fatty acids (4 g) alone and combination of simvastatin (20 mg) and ezetimibe (10 mg) and omega-3-fattyacids (4g) daily for 12weeks. After 12 weeks treatment (Tc, LDL)was found decreased, Tg level reduced significantly and HDL level increased in the combination therapy (Simvastatin, ezetimibe and omega-3-fattyacids) than monotherapy. From the result it is concluded that combination therapy of these three may be considered as an optimal treatment option for patients with mixed dyslipidemia.